A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

The outlook for patients with refractory/relapsed acute myeloid leukemia (AML) remains poor, with conventional chemotherapeutic treatments often associated with unacceptable toxicities, including severe infections due to profound myelosuppression. Thus there exists an urgent need for more effective...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V. J., Pinkas, Jan, Chittenden, Thomas
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916008/
https://ncbi.nlm.nih.gov/pubmed/29661755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017517
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki